WO2011133719A3 - Anti-viral compounds - Google Patents

Anti-viral compounds Download PDF

Info

Publication number
WO2011133719A3
WO2011133719A3 PCT/US2011/033322 US2011033322W WO2011133719A3 WO 2011133719 A3 WO2011133719 A3 WO 2011133719A3 US 2011033322 W US2011033322 W US 2011033322W WO 2011133719 A3 WO2011133719 A3 WO 2011133719A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
viral compounds
rig
pathway
viral infection
Prior art date
Application number
PCT/US2011/033322
Other languages
French (fr)
Other versions
WO2011133719A2 (en
Inventor
Shawn P. Iadonato
Kristin Bedard
Original Assignee
Kineta, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kineta, Inc. filed Critical Kineta, Inc.
Publication of WO2011133719A2 publication Critical patent/WO2011133719A2/en
Publication of WO2011133719A3 publication Critical patent/WO2011133719A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
    • C07D421/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.
PCT/US2011/033322 2010-04-23 2011-04-20 Anti-viral compounds WO2011133719A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32754310P 2010-04-23 2010-04-23
US61/327,543 2010-04-23

Publications (2)

Publication Number Publication Date
WO2011133719A2 WO2011133719A2 (en) 2011-10-27
WO2011133719A3 true WO2011133719A3 (en) 2012-04-05

Family

ID=44834795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/033322 WO2011133719A2 (en) 2010-04-23 2011-04-20 Anti-viral compounds

Country Status (2)

Country Link
TW (1) TW201202231A (en)
WO (1) WO2011133719A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180092A1 (en) 2017-10-13 2019-04-13 Gilead Sciences Inc Hiv protease inhibitors
TW202104210A (en) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv protease inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020990A1 (en) * 2003-07-30 2005-03-10 Centre National De La Recherche Scientifique Antibiotic thiazolidines
US7566732B2 (en) * 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020990A1 (en) * 2003-07-30 2005-03-10 Centre National De La Recherche Scientifique Antibiotic thiazolidines
US7566732B2 (en) * 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents

Also Published As

Publication number Publication date
TW201202231A (en) 2012-01-16
WO2011133719A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
WO2011133722A3 (en) Anti-viral compounds
WO2013049352A3 (en) Anti-viral compounds
WO2011133729A3 (en) Anti-viral compounds
WO2011133728A3 (en) Anti-viral compounds
WO2011133727A3 (en) Anti-viral compounds
WO2012166425A3 (en) Methods of amplifying whole genome of a single cell
WO2011056650A9 (en) Methods and compositions for treating and preventing viral infections
WO2012048099A3 (en) Nanoparticle-loaded cells
WO2014052836A3 (en) Methods and compositions for treating infection
WO2013049407A3 (en) Anti-viral compounds
WO2013119916A3 (en) Compounds for treating spinal muscular atrophy
WO2013075083A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013120104A3 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013075084A8 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013026740A3 (en) Methods and means to modify a plant genome
WO2012068589A3 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
WO2012083048A3 (en) Anti-viral compounds
MY181898A (en) Heterocyclic compounds and uses thereof
WO2012083053A3 (en) Anti-viral compounds
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
EP2527404A4 (en) Composition for ultraviolet ray-absorbable member, and ultraviolet ray-absorbable member comprising same
WO2012083061A3 (en) Anti-viral compounds
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
WO2013130963A8 (en) Compositions and methods for treating type iii gaucher disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11772672

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11772672

Country of ref document: EP

Kind code of ref document: A2